gliclazide and ramipril

Pharmacodynamic interaction. Ramipril, an ACE inhibitor, increases insulin sensitivity and reduces hepatic glucose output, thereby enhancing the glucose-lowering effect of gliclazide. It may also decrease insulin clearance and augment insulin-mediated glucose uptake in peripheral tissues, leading to an additive hypoglycaemic effect.

Patients taking gliclazide with ramipril may experience an exaggerated hypoglycaemic response. Symptoms such as sweating, tremor, palpitations, and confusion can occur. Severe hypoglycaemia is possible in susceptible individuals, especially during the initial weeks of ramipril therapy or after dose increases.

Monitor blood glucose more frequently when ramipril is started or its dose is changed. Advise the patient on recognising and managing hypoglycaemia. If hypoglycaemia occurs, consider reducing the gliclazide dose. This combination is not contraindicated, but close monitoring is recommended.

This interaction is well established in clinical trials and case reports. ACE inhibitors are known to potentiate the hypoglycaemic action of sulfonylureas, and this is recognised in several prescribing guidelines. The effect size varies among individuals, and the interaction is generally considered moderate in severity.